Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1994 May;49(5):479–484. doi: 10.1136/thx.49.5.479

Effect of increasing doses of beta agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airflow limitation.

R Jaeschke 1, G H Guyatt 1, A Willan 1, D Cook 1, S Harper 1, J Morris 1, H Ramsdale 1, R Haddon 1, M Newhouse 1
PMCID: PMC474870  PMID: 8016770

Abstract

BACKGROUND--A study was undertaken to determine the impact of different doses of inhaled terbutaline on peak flow rates, spirometric parameters, functional exercise capacity, and quality of life in patients with chronic airflow limitation. METHODS--A double blind, randomised, placebo controlled, multiple crossover trial was conducted with treatment periods of one week. Patients with a clinical diagnosis of chronic airflow limitation and FEV1 below 70% predicted after administration of bronchodilator were recruited from secondary care respiratory practices, and the effect of 500, 1000, and 1500 micrograms inhaled terbutaline four times daily on spirometric parameters (FEV1, FVC), maximum inspiratory pressures, six minute walking distance, and health-related quality of life (Chronic Respiratory Disease Questionnaire, Quality of Well Being, Standard Gamble) was measured. RESULTS--Twenty five patients completed the trial. Peak flow rates and FEV1 showed statistically significant but clinically trivial improvement on the higher drug doses. Results of maximum inspiratory pressure measurements, walk test distance, and quality of life measures showed minimal differences on the different dosages, and none of the differences approached conventional statistical significance. CONCLUSIONS--Regular use of beta agonists in doses higher than two puffs four times a day is very unlikely to provide additional functional or symptomatic benefit to patients with chronic airflow limitation.

Full text

PDF
479

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Assoufi B. K., Hodson M. E. High dose salbutamol in chronic airflow obstruction: comparison of nebulizer with Rotacaps. Respir Med. 1989 Sep;83(5):415–420. doi: 10.1016/s0954-6111(89)80073-3. [DOI] [PubMed] [Google Scholar]
  2. Brown I. G., Chan C. S., Kelly C. A., Dent A. G., Zimmerman P. V. Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation. Thorax. 1984 Apr;39(4):272–276. doi: 10.1136/thx.39.4.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chaieb J., Belcher N., Rees P. J. Maximum achievable bronchodilatation in asthma. Respir Med. 1989 Nov;83(6):497–502. doi: 10.1016/s0954-6111(89)80134-9. [DOI] [PubMed] [Google Scholar]
  4. Connolly C. K., Chan N. S. Salbutamol and ipratropium in partially reversible airway obstruction. Br J Dis Chest. 1987 Jan;81(1):55–61. doi: 10.1016/0007-0971(87)90108-2. [DOI] [PubMed] [Google Scholar]
  5. Corris P. A., Neville E., Nariman S., Gibson G. J. Dose-response study of inhaled salbutamol powder in chronic airflow obstruction. Thorax. 1983 Apr;38(4):292–296. doi: 10.1136/thx.38.4.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Freedman B. J. Trial of a terbutaline aerosol in the treatment of asthma and a comparison of its effects with those of a salbutamol aerosol. Br J Dis Chest. 1972 Jul;66(3):222–229. [PubMed] [Google Scholar]
  7. Georgopoulos D., Wong D., Anthonisen N. R. Tolerance to beta 2-agonists in patients with chronic obstructive pulmonary disease. Chest. 1990 Feb;97(2):280–284. doi: 10.1378/chest.97.2.280. [DOI] [PubMed] [Google Scholar]
  8. Guyatt G. H., Berman L. B., Townsend M., Pugsley S. O., Chambers L. W. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987 Oct;42(10):773–778. doi: 10.1136/thx.42.10.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Guyatt G. H., Keller J. L., Jaeschke R., Rosenbloom D., Adachi J. D., Newhouse M. T. The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann Intern Med. 1990 Feb 15;112(4):293–299. doi: 10.7326/0003-4819-112-4-293. [DOI] [PubMed] [Google Scholar]
  10. Guyatt G. H., Pugsley S. O., Sullivan M. J., Thompson P. J., Berman L., Jones N. L., Fallen E. L., Taylor D. W. Effect of encouragement on walking test performance. Thorax. 1984 Nov;39(11):818–822. doi: 10.1136/thx.39.11.818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Guyatt G. H., Townsend M., Pugsley S. O., Keller J. L., Short H. D., Taylor D. W., Newhouse M. T. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis. 1987 May;135(5):1069–1074. doi: 10.1164/arrd.1987.135.5.1069. [DOI] [PubMed] [Google Scholar]
  12. Guyatt G., Sackett D., Adachi J., Roberts R., Chong J., Rosenbloom D., Keller J. A clinician's guide for conducting randomized trials in individual patients. CMAJ. 1988 Sep 15;139(6):497–503. [PMC free article] [PubMed] [Google Scholar]
  13. Guyatt G., Sackett D., Taylor D. W., Chong J., Roberts R., Pugsley S. Determining optimal therapy--randomized trials in individual patients. N Engl J Med. 1986 Apr 3;314(14):889–892. doi: 10.1056/NEJM198604033141406. [DOI] [PubMed] [Google Scholar]
  14. Harding S. M., Freedman S. A comparison of oral and inhaled steroids in patients with chronic airways obstruction: features determining response. Thorax. 1978 Apr;33(2):214–218. doi: 10.1136/thx.33.2.214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jaeschke R., Guyatt G. H., Cook D., Morris J., Willan A., McIlroy W., Harper S., Ramsdale H., Haddon R., Fitzgerald M. J. The effect of increasing doses of beta-agonists on airflow in patients with chronic airflow limitation. Respir Med. 1993 Aug;87(6):433–438. doi: 10.1016/0954-6111(93)90069-c. [DOI] [PubMed] [Google Scholar]
  16. Jaeschke R., Singer J., Guyatt G. H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989 Dec;10(4):407–415. doi: 10.1016/0197-2456(89)90005-6. [DOI] [PubMed] [Google Scholar]
  17. Jenkins S. C., Heaton R. W., Fulton T. J., Moxham J. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest. 1987 Jun;91(6):804–807. doi: 10.1378/chest.91.6.804. [DOI] [PubMed] [Google Scholar]
  18. Jenkins S. C., Moxham J. High dose salbutamol in chronic bronchitis: comparison of 400 micrograms, 1 mg, 1.6 mg, 2 mg and placebo delivered by Rotahaler. Br J Dis Chest. 1987 Jul;81(3):242–247. doi: 10.1016/0007-0971(87)90156-2. [DOI] [PubMed] [Google Scholar]
  19. Kaplan R. M., Atkins C. J., Timms R. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J Chronic Dis. 1984;37(2):85–95. doi: 10.1016/0021-9681(84)90050-x. [DOI] [PubMed] [Google Scholar]
  20. Lipworth B. J., Clark R. A., Dhillon D. P., McDevitt D. G. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1990 Aug;142(2):338–342. doi: 10.1164/ajrccm/142.2.338. [DOI] [PubMed] [Google Scholar]
  21. Mahler D. A., Matthay R. A., Snyder P. E., Wells C. K., Loke J. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis. 1985 Jan;131(1):22–25. doi: 10.1164/arrd.1985.131.1.22. [DOI] [PubMed] [Google Scholar]
  22. Mestitz H., Copland J. M., McDonald C. F. Comparison of outpatient nebulized vs metered dose inhaler terbutaline in chronic airflow obstruction. Chest. 1989 Dec;96(6):1237–1240. doi: 10.1378/chest.96.6.1237. [DOI] [PubMed] [Google Scholar]
  23. Mitchell D. M., Gildeh P., Rehahn M., Dimond A. H., Collins J. V. Effects of prednisolone in chronic airflow limitation. Lancet. 1984 Jul 28;2(8396):193–196. doi: 10.1016/s0140-6736(84)90481-1. [DOI] [PubMed] [Google Scholar]
  24. Munzenberger P. J., Papaioanou H. A., Massoud N. A clinical comparison of terbutaline with albuterol administered by metered-dose inhaler. Ann Allergy. 1989 Feb;62(2):107–110. [PubMed] [Google Scholar]
  25. Murciano D., Auclair M. H., Pariente R., Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med. 1989 Jun 8;320(23):1521–1525. doi: 10.1056/NEJM198906083202304. [DOI] [PubMed] [Google Scholar]
  26. Patel A., Jaeschke R., Guyatt G. H., Keller J. L., Newhouse M. T. Clinical usefulness of n-of-1 randomized controlled trials in patients with nonreversible chronic airflow limitation. Am Rev Respir Dis. 1991 Oct;144(4):962–964. doi: 10.1164/ajrccm/144.4.962. [DOI] [PubMed] [Google Scholar]
  27. Prior J. G., Cochrane G. M. Assessment of optimum dose of inhaled terbutaline in patients with chronic asthma: the use of simple, cumulative dose-response curves. Br J Dis Chest. 1982 Jul;76(3):266–268. [PubMed] [Google Scholar]
  28. Sears M. R., Taylor D. R., Print C. G., Lake D. C., Li Q. Q., Flannery E. M., Yates D. M., Lucas M. K., Herbison G. P. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. doi: 10.1016/0140-6736(90)93098-a. [DOI] [PubMed] [Google Scholar]
  29. Simonsson B. G., Stiksa J., Ström B. Double-blind trial with increasing doses of salbutamol and terbutaline aerosols in patients with reversible airways obstruction. Acta Med Scand. 1972 Nov;192(5):371–376. doi: 10.1111/j.0954-6820.1972.tb04832.x. [DOI] [PubMed] [Google Scholar]
  30. Taylor D. R., Buick B., Kinney C., Lowry R. C., McDevitt D. G. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis. 1985 May;131(5):747–751. doi: 10.1164/arrd.1985.131.5.747. [DOI] [PubMed] [Google Scholar]
  31. Thiringer G., Svedmyr N. Evaluation of skeletal muscle tremor due to bronchodilator agents. Scand J Respir Dis. 1975 Aug;56(2):93–102. [PubMed] [Google Scholar]
  32. Torrance G. W. Measurement of health state utilities for economic appraisal. J Health Econ. 1986 Mar;5(1):1–30. doi: 10.1016/0167-6296(86)90020-2. [DOI] [PubMed] [Google Scholar]
  33. Tweeddale P. M., Alexander F., McHardy G. J. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax. 1987 Jul;42(7):487–490. doi: 10.1136/thx.42.7.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Tweeddale P. M., Merchant S., Leslie M., Alexander F., McHardy G. J. Short term variability in FEV1: relation to pretest activity, level of FEV1, and smoking habits. Thorax. 1984 Dec;39(12):928–932. doi: 10.1136/thx.39.12.928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Vathenen A. S., Britton J. R., Ebden P., Cookson J. B., Wharrad H. J., Tattersfield A. E. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis. 1988 Oct;138(4):850–855. doi: 10.1164/ajrccm/138.4.850. [DOI] [PubMed] [Google Scholar]
  36. van Schayck C. P., Dompeling E., van Herwaarden C. L., Folgering H., Verbeek A. L., van der Hoogen H. J., van Weel C. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ. 1991 Dec 7;303(6815):1426–1431. doi: 10.1136/bmj.303.6815.1426. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES